• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sensus Healthcare Announces Retirement of Director Samuel O'Rear

    2/1/24 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care
    Get the next $SRTS alert in real time by email

    BOCA RATON, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Samuel O'Rear will not stand for reelection to the Company's Board of Directors at the Company's 2024 annual meeting of stockholders.  Mr. O'Rear has been a Director of Sensus Healthcare since 2012.

    As previously announced, on January 11, 2024 the Board of Directors of Sensus Healthcare appointed Michael J. Sardano, President and General Counsel of Sensus Healthcare, as a Director, effective today.

    "Sam has been invaluable to the Board and to me personally since the inception of Sensus Healthcare more than a decade ago.  I wish him the same success in his retirement that he has had during his impressive business career. With appreciation and gratitude, thank you Sam O'Rear, for your years of dedicated service and support to our company and our shareholders, and for 30 years of friendship," said Joe Sardano, chairman and chief executive officer of Sensus Healthcare.

    "We also want to welcome Michael Sardano to the Board," he added.  "Michael has been responsible for many of the most important milestones achieved by Sensus since he joined the Team some 14 years ago, and he has gained the confidence and support of the Board and our shareholders. We look forward to many more contributions from him as our best years lie ahead."

    "I extend my thanks and appreciation to Joe, Michael, Javier and the Board of Directors, and to the dedicated employees of Sensus and its customers for their support of this great company," commented Mr. O'Rear.  "I have had the distinct pleasure of being part of Sensus from the very first days.  The healthcare industry has provided the opportunity to enjoy a very productive career, and my role with Sensus caps off 50 rewarding years of professional experiences."

    About Sensus Healthcare

    Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.

    Contact:

    LHA Investor Relations

    Kim Sutton Golodetz

    212-838-3777

    [email protected]

    #   #   #



    Primary Logo

    Get the next $SRTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRTS

    DatePrice TargetRatingAnalyst
    1/31/2025$18.00Buy
    Lake Street
    11/15/2024$12.00 → $14.00Buy
    Maxim Group
    3/3/2022$12.00 → $13.00Buy
    HC Wainwright & Co.
    2/14/2022$10.00 → $12.00Buy
    HC Wainwright & Co.
    12/2/2021$9.00 → $10.00Buy
    HC Wainwright & Co.
    11/5/2021$7.00 → $9.00Buy
    HC Wainwright & Co.
    8/6/2021$6.00 → $7.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SRTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sensus Healthcare Introduces Sensus Link, Brings Advanced Operating Capabilities to the SRT-100™ Installed Base

    Proprietary cloud-based software and add-on solution designed to provide current and future SRT-100 users with enhanced workflow, operating intelligence and clinical utility Creates a scalable, recurring-revenue opportunity for Sensus tied to treatment workflows and necessary oversight services Supports improved unit economics and expands Sensus' ability to serve Fair Deal Agreement customers and those who purchase a system Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, introduces Sensus Link, a cloud-based software and

    2/26/26 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Launches Sensus Healthcare Financial Services to Facilitate Customer Acquisition of SRT Technology

    New financing program provides a "one-stop" pathway for practices to acquire systems through outright purchase or several attractive leasing alternatives Supports improved conversion of late-stage prospects as reimbursement clarity accelerates purchase decisions and lowers breakeven point to only one patient per month Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the launch of Sensus Healthcare Financial Services, a new program intended to make it easier for dermatology practices to acquire Sensus' superficial r

    2/18/26 8:30:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Reports Fourth Quarter 2025 Financial Results Highlighted by Publication of Dedicated CPT Codes for SRT to Treat Non-Melanoma Skin Cancer

    2026 CMS Physician Fee Schedule Final Rule provides a 300% per-fraction increase to delivery code that became effective January 1, 2026 Company enters 2026 with reimbursement certainty and strategic visibility, expects sequential-quarter revenue growth in Q1 and full-year profitability Shipped 14 SRT systems in Q4, most in December and none to its historically largest customer, up from six systems in Q3 excluding shipments to its historically largest customer Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for onc

    2/12/26 4:05:00 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sachetta Eric bought $7,620 worth of shares (2,000 units at $3.81), increasing direct ownership by 1% to 142,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    2/26/26 9:25:34 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Biscotti Larry Joseph

    3 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    2/18/26 3:48:31 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    PRESIDENT AND GENERAL COUNSEL Sardano Michael was granted 40,000 shares, increasing direct ownership by 34% to 158,839 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    12/16/25 2:40:20 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sachetta Eric bought $7,620 worth of shares (2,000 units at $3.81), increasing direct ownership by 1% to 142,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    2/26/26 9:25:34 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Director Sachetta Eric bought $27,510 worth of shares (7,000 units at $3.93), increasing direct ownership by 5% to 140,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/21/25 2:28:31 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Director Sachetta Eric bought $11,250 worth of shares (2,500 units at $4.50), increasing direct ownership by 2% to 133,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/20/25 2:03:11 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Sensus Healthcare with a new price target

    Lake Street initiated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $18.00

    1/31/25 9:07:11 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Maxim Group reiterated coverage on Sensus Healthcare with a new price target

    Maxim Group reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $14.00 from $12.00 previously

    11/15/24 8:09:06 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    HC Wainwright & Co. reiterated coverage on Sensus Healthcare with a new price target

    HC Wainwright & Co. reiterated coverage of Sensus Healthcare with a rating of Buy and set a new price target of $13.00 from $12.00 previously

    3/3/22 6:32:52 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    SEC Filings

    View All

    Sensus Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Sensus Healthcare, Inc. (0001494891) (Filer)

    2/12/26 4:09:22 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - Sensus Healthcare, Inc. (0001494891) (Filer)

    1/20/26 11:07:30 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Sensus Healthcare, Inc. (0001494891) (Filer)

    1/9/26 7:25:06 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    Leadership Updates

    Live Leadership Updates

    View All

    Sensus Healthcare Appoints Larry Biscotti to its Board of Directors

    Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Larry Biscotti to its Board of Directors, effective immediately. With this appointment the Sensus Healthcare Board has six Directors, including four independent Directors. Mr. Biscotti brings more than 25 years of executive leadership experience in the medical device and healthcare technology sectors, with an extensive background in driving commercial strategy, expanding global market share and launching advanced imaging and oncology technologi

    1/7/26 8:30:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Appoints Eric Sachetta to its Board of Directors

    Seasoned financial executive brings leadership acumen, strategic growth expertise and a strong track record of operational excellence Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Eric Sachetta to the Company's Board of Directors. Mr. Sachetta is filling the vacancy that resulted from the passing of long-serving Director Bill McCall. Throughout his career, Mr. Sachetta has held a range of leadership roles focused on organizational growth, team development, sales performance and operation

    11/12/25 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Celebrates Skin Cancer Awareness Month by Promoting Awareness and Spotlighting its Patient-Friendly, Non-Invasive Treatments

    Innovative SRT-100 Vision (IG-SRT) and SRT Vision Technologies allow dermatologists to treat non-melanoma skin cancer without surgery or patient downtime May is Skin Cancer Awareness Month and Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, is leveraging a wide range of activities to draw attention to the importance of prevention, early detection and treatment of the most common form of cancer that affects millions of people worldwide. Throughout the month of May, Sensus Healthcare is actively promoting skin cancer awareness

    5/1/25 4:30:00 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    Financials

    Live finance-specific insights

    View All

    Sensus Healthcare Reports Fourth Quarter 2025 Financial Results Highlighted by Publication of Dedicated CPT Codes for SRT to Treat Non-Melanoma Skin Cancer

    2026 CMS Physician Fee Schedule Final Rule provides a 300% per-fraction increase to delivery code that became effective January 1, 2026 Company enters 2026 with reimbursement certainty and strategic visibility, expects sequential-quarter revenue growth in Q1 and full-year profitability Shipped 14 SRT systems in Q4, most in December and none to its historically largest customer, up from six systems in Q3 excluding shipments to its historically largest customer Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for onc

    2/12/26 4:05:00 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare to Report Fourth Quarter and Full Year 2025 Financial Results and Hold Business Update Conference Call on February 12, 2026

    Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions. Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after t

    2/5/26 8:00:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Sensus Healthcare Reports Third Quarter 2025 Financial Results

    Centers for Medicare & Medicaid Services (CMS) established coding validating superficial radiotherapy (SRT) for treating non-melanoma skin cancer Revenues of $6.9 million Shipped 16 SRT systems including three to China Fair Deal Agreement (FDA) treatment volume increased 20% over the second quarter Exited the quarter with $24.5 million in cash and no debt Conference call begins at 4:30 p.m. Eastern time today Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months end

    11/6/25 4:05:00 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $SRTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)

    SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)

    2/6/24 12:27:47 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)

    SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)

    2/10/23 11:51:22 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Sensus Healthcare Inc. (Amendment)

    SC 13G/A - Sensus Healthcare, Inc. (0001494891) (Subject)

    2/7/22 8:30:08 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care